drugset / Trial / NCT07072234
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
Timeline
- Start
- 2025-09-25
- Primary completion
- 2028-02-01
- Completion
- 2030-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGFBR-2 KO CD70 CAR NK | Cell therapy | — | Intravenous |
| Background | Cyclophosphamate | Unknown | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Fludarabine | Small molecule | — | Intravenous |